mHag UTA2-1 loaded PD-L silenced DC vaccination after allo SCT
- Conditions
- Multipel Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin Lymphoma (NHL)Acute Myeloide Leukemie (AML)
- Registration Number
- NL-OMON22602
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 17
1. Patients with Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL) or non hodgkin lymphoma (any grade) or acute myeloid leukemia (AML)
2. Recipient and donor have a mismatch in UTA2-1 mHag in the Graft versus Tumor (GvT) direction (recipient UTA2-1 positive, donor UTA2-1 negative).
4. Recipient and donor are positive for HLA-A*0201
5. Age 18-75 years
6. Absence of acute GvHD > grade 2 or extensive chronic GvHD
7. No treatment with immunosuppressive drugs such as prednisone, cyclosporine A and MMF at least 4 weeks prior to planned vaccination date.
8. WHO performance 0-2
9. Absence of severe cardiac hepatic, renal, or metabolic disease
10. Written informed consent
1. WHO performance 3-4
2. Presence of severe cardiac hepatic, renal, metabolic disease
3. Rapidly progressive disease,
4. Life expectancy < 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -To evaluate the toxicity and feasibility of a preemptive minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC<br> vaccination<br> - To evaluate the effect of minor H ag UTA2-1 peptide-loaded, PD-L1/2 silenced donor DC vaccination on the immune<br> status of the recipient in correlation with the induction of UTA2-1 specific T cell responses after vaccination.
- Secondary Outcome Measures
Name Time Method -to evaluate the efficacy of the minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination to induce a<br> GvT effect.